AXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS Patients
January 23, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), the world leader in cannabinoid research and development, announced today that it has successfully completed an...
Earth Science Tech, Inc. Announces New Agreement with a Private Laboratory to Develop and Commercialize MSN-2 Medical Device
January 09, 2018 08:00 ET
|
Earth Science Tech, Inc.
Doral, FL,, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or, the “Company"), an innovative biotech company that operates in the fields of hemp cannabinoid...
Emerald Health Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference
January 05, 2018 11:30 ET
|
Emerald Health Pharmaceuticals Inc.
SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that it will present at Biotech...
AXIM Biotech Attends Biotech Showcase Conference in San Francisco
January 04, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov,...
Earth Science Tech, Inc. Announces a Successful Two-Day SOHO Expo
December 05, 2017 08:00 ET
|
Earth Science Tech, Inc.
ETST Corporate Brand Well Received at EXPO; Opening New Accounts, Both Retail and Wholesale Doral, FL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the...
Axim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)
November 21, 2017 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results...
IGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical Dispensaries
October 18, 2017 08:00 ET
|
India Globalization Capital
BETHESDA, Md., Oct. 18, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides compelling in vitro data compiled from genetically engineered cell lines within an...
New U.S. Patent Allowance Granted to AXIM® Biotechnologies, Inc. for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis Treatment
October 05, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the United States...
AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City
September 07, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
CURE Pharmaceutical to Participate in Panel Discussion on the Future of Clinical Research using Cannabis at The Cannabis Science Conference in Portland, OR
August 29, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., Aug. 29, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...